ResearcherUniversity Health NetworkActive in the last 2 years
Sheron Perera
Matched on ORCID iD 0000-0001-8048-0611; OpenAlex author ID A5053818648. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper
Papers 5
- Adjuvant Chemoradiotherapy for Pancreatic Adenocarcinoma. First author DOI 10.1016/j.soc.2025.04.006↗
- Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
- Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. Co-author DOI 10.1136/jclinpath-2021-207781↗
- hENT1 as a Predictive Biomarker in PDAC-Response. Co-author DOI 10.1158/1078-0432.ccr-23-0887↗
- hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Robert C. Grant · 4 shared papers, 2022–2025 · strength 0.61
- Paper hENT1 as a Predictive Biomarker in PDAC-Response. DOI 10.1158/1078-0432.ccr-23-0887↗
- Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Grainne Mary O'Kane · 4 shared papers, 2022–2025 · strength 0.61
- Paper hENT1 as a Predictive Biomarker in PDAC-Response. DOI 10.1158/1078-0432.ccr-23-0887↗
- Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Jennifer Jane Knox · 4 shared papers, 2022–2025 · strength 0.61
- Paper hENT1 as a Predictive Biomarker in PDAC-Response. DOI 10.1158/1078-0432.ccr-23-0887↗
- Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Steve Gallinger · 4 shared papers, 2022–2025 · strength 0.61
- Paper hENT1 as a Predictive Biomarker in PDAC-Response. DOI 10.1158/1078-0432.ccr-23-0887↗
- Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Faiyaz Notta · 4 shared papers, 2022–2025 · strength 0.61
- Paper hENT1 as a Predictive Biomarker in PDAC-Response. DOI 10.1158/1078-0432.ccr-23-0887↗
- Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Natalie G. Coburn · 1 shared paper, 2026 · strength 0.50
- Sylvia S. W. Ng · 1 shared paper, 2026 · strength 0.50
- Sandra Elisabeth Fischer · 3 shared papers, 2022–2025 · strength 0.41
- Paper Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. DOI 10.1038/s41467-025-60808-z↗
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-22-2576↗
- Barbara T. Grünwald · 2 shared papers, 2023–2025 · strength 0.35
- Ravi Ramjeesingh · 2 shared papers, 2022–2025 · strength 0.27
- Mustapha Ali Tehfe · 2 shared papers, 2022–2025 · strength 0.27
- Yifan Wang · 2 shared papers, 2022–2025 · strength 0.27
- George Zogopoulos · 2 shared papers, 2022–2025 · strength 0.27
- Michael J. Allen · 2 shared papers, 2022–2023 · strength 0.26
- Paper Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. DOI 10.1136/jclinpath-2021-207781↗
- Paper hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1078-0432.ccr-22-2576↗
- Spring Holter · 1 shared paper, 2025 · strength 0.15
- Sangeetha N. Kalimuthu · 1 shared paper, 2025 · strength 0.15
- Joan Miguel Romero · 1 shared paper, 2025 · strength 0.15
- Raymond Jang · 1 shared paper, 2025 · strength 0.15
- Michelle Chan‐Seng‐Yue · 1 shared paper, 2025 · strength 0.15
- Erica S. Tsang · 1 shared paper, 2025 · strength 0.15
- Malcolm J. Moore · 1 shared paper, 2025 · strength 0.15
- Tae Kyoung Kim · 1 shared paper, 2025 · strength 0.15
- Kyaw Lwin Aung · 1 shared paper, 2025 · strength 0.15
- James Biagi · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.